Singapore, Oct. 15 -- A team of researchers from Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and China's Tsinghua University has unveiled a new messenger ribonucleic acid (mRNA) vaccine technology that could make future vaccines safer, more effective, and less burdensome for patients.

Published in Nature Materials, the new approach uses albumin-recruiting lipid nanoparticles, called Evans Blue-modified lipid nanoparticles (EB-LNP), to deliver mRNA precisely to lymph nodes, which are immune system "command centres", while bypassing the liver, a common site of toxicity for current vaccines. In laboratory tests, the technique outperformed traditional delivery systems in both cancer treatment and viral in...